Weinberger v. Bentex Pharmaceuticals, Inc.
Headline: Drug makers lose as Court allows the FDA to decide whether marketed “me‑too” drugs are “new drugs,” reversing the appeals court and sending technical safety-effectiveness questions back to the agency.
Holding: The Court held that the FDA has authority to decide administratively whether marketed drugs are “new drugs” needing NDAs, and that district courts should refer those technical questions to the agency.
- Requires courts to refer technical drug safety-effectiveness questions to the FDA.
- Allows FDA to remove or classify many marketed “me‑too” drugs without separate court trials.
- Promotes uniform regulation and avoids piecemeal lawsuits by competing manufacturers.
Summary
Background
Bentex and about twenty other companies that market drugs containing pentylenetetrazol sued to declare their products generally recognized as safe and effective and therefore not “new drugs” under the Act. The FDA, after three expert National Academy of Sciences–National Research Council panels found the drugs ineffective, moved to withdraw approval of three new drug applications (NDAs). The FDA also said withdrawing those NDAs would affect many similar “me‑too” products on the market, and it invited interested parties to submit evidence; only one NDA holder submitted data and it was rejected.
Reasoning
The Court considered whether courts should decide the technical question of “new drug” status or whether the FDA can decide it in administrative proceedings. The Court held that deciding whether a drug is generally recognized as safe and effective depends on scientific expertise and controlled clinical evidence—matters suited to the FDA. It emphasized that allowing courts to handle each drug de novo would overwhelm the agency and lead to inconsistent results, so courts should refer such technical issues to the FDA for initial administrative determination.
Real world impact
The decision means the FDA can determine with administrative finality whether marketed drugs need NDAs, subject to the statutory review processes. That power lets the agency handle large numbers of products more uniformly; by May 1972, FDA final orders had withdrawn approvals affecting hundreds of NDAs and led to the removal of over a thousand “me‑too” drugs. The ruling does not foreclose later judicial review of agency actions through the established review procedures.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?